Trial Profile
INFORM-3
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 10 Jan 2011
Price :
$35
*
At a glance
- Drugs Mericitabine (Primary) ; Danoprevir; Peginterferon alfa-2a; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms INFORM-3; INFORM-SVR
- Sponsors Roche
- 06 Jan 2011 Trial expected to be initiated in the first quarter of 2011, according to a Pharmasset media release.
- 06 Jan 2011 Planned initiation date changed to 1 Jan 2011.
- 23 Feb 2010 New trial record